XBiotech completed a groundbreaking clinical study in cardiovascular medicine. This Phase II randomized, multi-center clinical study evaluated a True Human™ therapeutic antibody MABp1 (bermekimab) for its ability to reduce adverse events after balloon angioplasty, atherectomy, or stent placement in patients undergoing revascularization procedures for blockage of a major artery. This drug development program has U.S. FDA Fast Track designation.
Phase II Randomized Study Results
Clinical results demonstrated a reduction in restenosis and reduced incidence of Major Adverse Cardiovascular Events (MACE) in treated patients compared to controls
Study suggests beneficial treatment effect at 15 weeks
Vascular disease is currently one of the most common causes of death in both developed countries and emerging economic regions. While there has been significant research, technology has largely centered around angioplasty and the use of stents to open affected arteries and maintain patency, respectively.
Limitation of Current Treatments
Potential benefits are often only temporary
Treated arteries can re-occlude (restenosis)
Benefits of Using an Anti-IL-1α True Human™ Antibody
Inhibit white blood cell infiltration of the artery
Reduce arterial inflammation after angioplasty procedures
Reduce incidence or severity of restenosis